BIOME AUSTRALIA ORD
Biome Australia Launches First Human Clinical Trial on Proprietary BMB18 Strain
Biome Australia (ASX: BIO) has submitted ethics approval and registered its first human clinical trial on proprietary probiotic strain Lactobacillus plantarum BMB18 with the Australia New Zealand Clinical Trials Registry.
Biome Australia Expands Retail Distribution with Mecca and Go Vita Partnerships
Biome Australia (ASX: BIO) has struck new distribution agreements with Mecca and Go Vita, marking a significant expansion for its flagship Activated Probiotics range into both premium beauty and mainstream health food retail. The company said the partnerships represent a turning point in its distribution strategy, extending reach into high-traffic retail environments while reinforcing its […]
Market wrap: Australia ignores Wall Street record on faltering miners
The Australian share market once again ignored a rally on Wall Street to a fresh record high and closed down 0.3% thanks to a broad-based slump on Friday. It was yet another reminder of how the Australian bourse with its heavy concentration of miners and banks has disconnected from the Artificial Intelligence rally that is […]
Biome Australia expects to surpass FY24 earnings guidance on back of record sales revenue
Biome Australia (ASX: BIO) is on target to easily beat its 2024 financial year forecast after a strong period of revenue. The microbiome health specialist had predicted FY2024 earnings of $12.5 million but record sales numbers for April and May have increased expectations. This follows the company’s initial $11.5m estimate announced in October 2023 being […]
